犬肝细胞癌分子靶向治疗候选基因。

IF 1.6 Q2 MULTIDISCIPLINARY SCIENCES

BMC Research Notes Pub Date : 2024-12-02 DOI:10.1186/s13104-024-07016-y

Toshiyuki Tanaka, Tomoki Motegi, Misaki Mori, Nanami Sumikawa, Kaito Maeda, Yasumasa Iimori, Hideo Akiyoshi

{"title":"犬肝细胞癌分子靶向治疗候选基因。","authors":"Toshiyuki Tanaka, Tomoki Motegi, Misaki Mori, Nanami Sumikawa, Kaito Maeda, Yasumasa Iimori, Hideo Akiyoshi","doi":"10.1186/s13104-024-07016-y","DOIUrl":null,"url":null,"abstract":"Objectives: Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.Data description: Liver specimens were obtained from 11 dogs with HCC and four dogs without HCC. We performed RNA seq using the mRNA extracted from the specimens. Differentially expressed genes (DEGs) between canine HCC and normal liver were explored based on previously reported molecular-targeted agents for human tumours. PARP3, DNMT1, FGF19, FGF23, and RET DEGs were upregulated, whereas KIT, FGFR2, and FGF21 DEGs were downregulated.","PeriodicalId":9234,"journal":{"name":"BMC Research Notes","volume":"17 1","pages":"357"},"PeriodicalIF":1.6000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613665/pdf/","citationCount":"0","resultStr":"{\"title\":\"Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy.\",\"authors\":\"Toshiyuki Tanaka, Tomoki Motegi, Misaki Mori, Nanami Sumikawa, Kaito Maeda, Yasumasa Iimori, Hideo Akiyoshi\",\"doi\":\"10.1186/s13104-024-07016-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.Data description: Liver specimens were obtained from 11 dogs with HCC and four dogs without HCC. We performed RNA seq using the mRNA extracted from the specimens. Differentially expressed genes (DEGs) between canine HCC and normal liver were explored based on previously reported molecular-targeted agents for human tumours. PARP3, DNMT1, FGF19, FGF23, and RET DEGs were upregulated, whereas KIT, FGFR2, and FGF21 DEGs were downregulated.\",\"PeriodicalId\":9234,\"journal\":{\"name\":\"BMC Research Notes\",\"volume\":\"17 1\",\"pages\":\"357\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-12-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613665/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Research Notes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s13104-024-07016-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Research Notes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13104-024-07016-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

摘要

目的：不可切除的犬肝细胞癌（HCC）的非手术治疗选择有限。索拉非尼是不可切除犬肝细胞癌的靶向治疗。然而，关于靶基因表达的报道有限。因此，靶向治疗犬肝癌的疗效尚不清楚。资料描述：11只肝癌犬和4只非肝癌犬的肝脏标本。我们使用从标本中提取的mRNA进行RNA测序。犬肝癌与正常肝脏之间的差异表达基因（DEGs）基于先前报道的人类肿瘤分子靶向药物进行了探索。PARP3、DNMT1、FGF19、FGF23和RET基因上调，而KIT、FGFR2和FGF21基因下调。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy.

Objectives: Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.

Data description: Liver specimens were obtained from 11 dogs with HCC and four dogs without HCC. We performed RNA seq using the mRNA extracted from the specimens. Differentially expressed genes (DEGs) between canine HCC and normal liver were explored based on previously reported molecular-targeted agents for human tumours. PARP3, DNMT1, FGF19, FGF23, and RET DEGs were upregulated, whereas KIT, FGFR2, and FGF21 DEGs were downregulated.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

BMC Research Notes Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)

CiteScore

3.60

自引率

0.00%

发文量

363

审稿时长

15 weeks

期刊介绍： BMC Research Notes publishes scientifically valid research outputs that cannot be considered as full research or methodology articles. We support the research community across all scientific and clinical disciplines by providing an open access forum for sharing data and useful information; this includes, but is not limited to, updates to previous work, additions to established methods, short publications, null results, research proposals and data management plans.